Negative hyperselection of resistance mutations for panitumumab maintenance in RAS wild-type metastatic colorectal cancer (PanaMa phase II trial, AIO KRK 0212)

CONCLUSIONS: Extended molecular profiling beyond RAS may have the potential to improve of the patient selection for anti-EGFR containing maintenance regimens.PMID:38289994 | DOI:10.1158/1078-0432.CCR-23-3023

Source: Clinical Cancer Research - January 30, 2024 Category: Cancer & Oncology Authors: Arndt Stahler Andreas J Kind Christine Sers Soulafa Mamlouk Lothar M üller Meinolf Karthaus Stefan Fr ühauf Ullrich Graeven Ludwig Fischer von Weikersthal Greta Sommerh äuser Stefan Kasper Beeke Hoppe Annika Kurreck Swantje Held Volker Heinemann David Source Type: research